Aitia
Aitia utilizes Gemini Digital Twins for AI-driven drug discovery, focusing on neurodegenerative diseases, and collaborates with industry leaders to develop breakthrough therapies.
AI-Driven Drug Discovery
Aitia specializes in AI-driven drug discovery with a particular focus on neurodegenerative diseases. By harnessing advanced artificial intelligence algorithms, the company aims to develop breakthrough therapies that address the rapid and devastating impacts these diseases have on patients and their families. Aitia's innovative approach allows for the identification of new drug targets and the development of novel treatments.
Gemini Digital Twins
Aitia utilizes Gemini Digital Twins in its drug discovery process. These digital twins are computational representations of diseases that capture genetic and molecular interactions that causally drive clinical and physiological outcomes. This cutting-edge technology enables Aitia to simulate and analyze the complexities of diseases, leading to better understanding and more effective therapeutic interventions.
Collaborations with Industry Leaders
Aitia collaborates with industry-leading companies across diverse therapeutic areas to discover breakthrough therapies. These collaborations are crucial in pooling expertise and resources, accelerating the development of novel treatments. Through partnerships, Aitia leverages external knowledge and technologies to enhance its drug discovery pipeline.
Location and Contact Information
Aitia is located at 561 Windsor St, Somerville, MA 02143. For inquiries, they can be contacted by phone at 617.374.2300. The company's strategic location facilitates collaboration with surrounding academic and industry partners, fostering a vibrant ecosystem for innovative research and development.